Compare Stocks: CUE, OLMA, NVCT, and VSTM

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CUE Cue Biopharma	$25.57 +1.3%	$28.64	$4.97 ▼ $45.50	$183.43M	2.61	440,394 shs	156,834 shs
NVCT Nuvectis Pharma	$21.92 +5.8%	$21.86	$5.55 ▼ $29.27	$715.56M	-0.24	199,515 shs	207,490 shs
OLMA Olema Pharmaceuticals	$8.23 -0.5%	$10.44	$6.65 ▼ $36.26	$719.67M	2	1.24 million shs	1.07 million shs
VSTM Verastem	$7.70 -2.5%	$7.21	$3.43 ▼ $10.82	$697.34M	0.39	2.18 million shs	4.07 million shs

The Best Nuclear Energy Stocks to Buy

Nuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CUE Cue Biopharma	+1.27%	-18.59%	-5.16%	-9.52%	-96.07%
NVCT Nuvectis Pharma	+5.79%	+8.41%	-8.36%	+12.01%	+261.72%
OLMA Olema Pharmaceuticals	-0.48%	-5.94%	-24.01%	-34.89%	-25.45%
VSTM Verastem	-2.53%	-0.52%	-3.99%	+71.11%	-12.50%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CUE Cue Biopharma	$25.57 +1.3%	$28.64	$4.97 ▼ $45.50	$183.43M	2.61	440,394 shs	156,834 shs
NVCT Nuvectis Pharma	$21.92 +5.8%	$21.86	$5.55 ▼ $29.27	$715.56M	-0.24	199,515 shs	207,490 shs
OLMA Olema Pharmaceuticals	$8.23 -0.5%	$10.44	$6.65 ▼ $36.26	$719.67M	2	1.24 million shs	1.07 million shs
VSTM Verastem	$7.70 -2.5%	$7.21	$3.43 ▼ $10.82	$697.34M	0.39	2.18 million shs	4.07 million shs

The Best Nuclear Energy Stocks to Buy

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CUE Cue Biopharma	+1.27%	-18.59%	-5.16%	-9.52%	-96.07%
NVCT Nuvectis Pharma	+5.79%	+8.41%	-8.36%	+12.01%	+261.72%
OLMA Olema Pharmaceuticals	-0.48%	-5.94%	-24.01%	-34.89%	-25.45%
VSTM Verastem	-2.53%	-0.52%	-3.99%	+71.11%	-12.50%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CUE Cue Biopharma	2.33	Hold	$83.00	224.60% Upside
NVCT Nuvectis Pharma	2.80	Moderate Buy	$36.25	65.37% Upside
OLMA Olema Pharmaceuticals	2.77	Moderate Buy	$40.60	393.32% Upside
VSTM Verastem	2.73	Moderate Buy	$13.83	79.65% Upside

Current Analyst Ratings Breakdown

Latest CUE, OLMA, NVCT, and VSTM Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
9/28/2026	VSTM Verastem	Cantor Fitzgerald Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Overweight
9/24/2026	NVCT Nuvectis Pharma	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$39.00
9/21/2026	NVCT Nuvectis Pharma	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
9/21/2026	OLMA Olema Pharmaceuticals	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
9/21/2026	CUE Cue Biopharma	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Hold
9/18/2026	CUE Cue Biopharma	B. Riley Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy	$83.00
9/18/2026	CUE Cue Biopharma	B. Riley Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy	$83.00
9/17/2026	CUE Cue Biopharma	B. Riley Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Strong-Buy
9/17/2026	VSTM Verastem	Wolfe Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Outperform
9/14/2026	OLMA Olema Pharmaceuticals	Stifel Nicolaus Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Buy	$48.00 ➝ $30.00
9/11/2026	VSTM Verastem	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$18.00

(Data available from 10/3/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CUE Cue Biopharma	$37.66M	4.93	N/A	N/A	$10.08 per share	2.54
NVCT Nuvectis Pharma	N/A	N/A	N/A	N/A	$0.72 per share	N/A
OLMA Olema Pharmaceuticals	N/A	N/A	N/A	N/A	$5.88 per share	N/A
VSTM Verastem	$87.53M	7.97	N/A	N/A	$0.74 per share	10.41

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CUE Cue Biopharma	-$26.60M	-$27.02	N/A	N/A	N/A	-435.83%	-620.06%	-291.15%	11/11/2026 (Estimated)
NVCT Nuvectis Pharma	-$26.44M	-$1.31	N/A	N/A	N/A	N/A	-184.25%	-105.24%	11/3/2026 (Estimated)
OLMA Olema Pharmaceuticals	-$162.45M	-$2.12	N/A	N/A	N/A	N/A	-48.26%	-43.04%	11/9/2026 (Estimated)
VSTM Verastem	-$209.47M	-$2.66	N/A	N/A	N/A	-231.59%	-467.49%	-94.54%	11/3/2026 (Estimated)

Latest CUE, OLMA, NVCT, and VSTM Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/14/2026	Q2 2026	CUE Cue Biopharma	-$1.69	-$24.14	-$22.45	-$24.14	$3.00 million	$7.88 million
8/10/2026	Q2 2026	OLMA Olema Pharmaceuticals	-$0.5515	-$0.61	-$0.0585	-$0.61	N/A	N/A
8/6/2026	Q2 2026	VSTM Verastem	-$0.4305	-$0.35	+$0.0805	-$0.35	$22.88 million	$40.08 million
8/4/2026	Q2 2026	NVCT Nuvectis Pharma	-$0.2620	-$0.30	-$0.0380	-$0.30	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
CUE Cue Biopharma	N/A	N/A	N/A	N/A	N/A
NVCT Nuvectis Pharma	N/A	N/A	N/A	N/A	N/A
OLMA Olema Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
VSTM Verastem	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CUE Cue Biopharma	N/A	1.25	1.25
NVCT Nuvectis Pharma	N/A	1.68	1.68
OLMA Olema Pharmaceuticals	0.01	8.86	8.86
VSTM Verastem	1.48	2.25	2.22

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CUE Cue Biopharma	35.04%
NVCT Nuvectis Pharma	96.77%
OLMA Olema Pharmaceuticals	91.78%
VSTM Verastem	88.37%

Insider Ownership

Company	Insider Ownership
CUE Cue Biopharma	14.56%
NVCT Nuvectis Pharma	28.55%
OLMA Olema Pharmaceuticals	12.56%
VSTM Verastem	1.94%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CUE Cue Biopharma	29	7.26 million	6.21 million	Optionable
NVCT Nuvectis Pharma	13	32.64 million	23.32 million	Not Optionable
OLMA Olema Pharmaceuticals	150	87.50 million	76.51 million	Optionable
VSTM Verastem	102	90.56 million	88.81 million	Optionable

CUE, OLMA, NVCT, and VSTM Headlines

Recent News About These Companies

Verastem (NASDAQ:VSTM) CFO Daniel Calkins Sells 2,566 Shares of Stock

October 3 at 6:22 AM | americanbankingnews.com

Verastem (NASDAQ:VSTM) CFO Sells 2,566 Shares of Stock

October 3 at 5:52 AM | insidertrades.com

Verastem (NASDAQ:VSTM) CEO Dan Paterson Sells 44,121 Shares of Company Stock

October 3 at 5:38 AM | americanbankingnews.com

Verastem (NASDAQ:VSTM) CFO Sells 2,566 Shares of Company Stock

October 2 at 7:07 PM | marketbeat.com

Verastem (NASDAQ:VSTM) CEO Sells $352,968.00 in Stock

October 2 at 7:07 PM | marketbeat.com

Verastem Oncology Announces New RAMP 201 Molecular Profiling and External Control Arm Analyses Describing Outcomes for Avutometinib Plus Defactinib in Recurrent Low-Grade ...

October 2 at 12:04 PM | finance.yahoo.com

Verastem Oncology Announces New RAMP 201 Molecular Profiling and External Control Arm Analyses Describing Outcomes for Avutometinib Plus Defactinib in Recurrent Low-Grade Serous Ovarian Cancer to be Presented at IGCS 2026

October 2 at 8:00 AM | businesswire.com

Head-To-Head Analysis: ADC Therapeutics (NYSE:ADCT) vs. Verastem (NASDAQ:VSTM)

October 1 at 2:15 AM | americanbankingnews.com

Verastem Oncology Announces Publication in Gynecologic Oncology of Two-Year Median Follow-Up Data from RAMP 201 Study of AVMAPKI® FAKZYNJA® CO-PACK (avutometinib capsules ...

September 29, 2026 | marketscreener.comM

Financial Review: Sangamo Therapeutics (NASDAQ:SGMO) versus Verastem (NASDAQ:VSTM)

September 29, 2026 | americanbankingnews.com

Verastem Oncology Announces Publication in Gynecologic Oncology of Two-Year Median Follow-Up Data from RAMP 201 Study of AVMAPKI® FAKZYNJA® CO-PACK (avutometinib capsules; defactinib tablets) in Recurrent Low-Grade Serous Ovarian Cancer

September 28, 2026 | businesswire.com

Financial Comparison: Nektar Therapeutics (NASDAQ:NKTR) and Verastem (NASDAQ:VSTM)

September 27, 2026 | americanbankingnews.com

Verastem (NASDAQ:VSTM) Raised to "Hold" at Wall Street Zen

September 27, 2026 | americanbankingnews.com

Verastem (NASDAQ:VSTM) Upgraded to Hold at Wall Street Zen

September 27, 2026 | marketbeat.com

Verastem data on ovarian cancer drug combo set for IGCS 2026

September 25, 2026 | streetinsider.com

Verastem Oncology Announces Late-Breaking Oral Presentation of RAMP 201 Low-Grade Serous Ovarian Cancer Molecular Profiling and Tumor Biomarker Analysis at IGCS 2026 Annual Global Meeting

September 24, 2026 | businesswire.com

Verastem (NASDAQ:VSTM) Shares Up 7.1% - Still a Buy?

September 22, 2026 | marketbeat.com

Verastem Highlights Ovarian Cancer Launch, KRAS G12D Program at H.C. Wainwright

September 21, 2026 | marketbeat.com

Verastem, Inc. (NASDAQ:VSTM) Given Consensus Recommendation of "Moderate Buy" by Brokerages

September 21, 2026 | marketbeat.com

Verastem's Shares Not Fully Valuing its Growth Potential, RBC Says

September 19, 2026 | finance.yahoo.com

Verastem (NASDAQ:VSTM) Downgraded by Wall Street Zen to "Sell"

September 19, 2026 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

CUE, OLMA, NVCT, and VSTM Company Descriptions

Cue Biopharma NASDAQ:CUE

$25.57 +0.32 (+1.27%)

Closing price 10/2/2026 04:00 PM Eastern

Extended Trading

$25.55 -0.02 (-0.06%)

As of 10/2/2026 07:56 PM Eastern

Cue Biopharma, Inc., a clinical-stage biopharmaceutical company, develops a novel class of injectable therapeutics to selectively engage and modulate targeted, disease relevant T cells directly within the patient's body. Its lead drug product candidate is CUE-101 for the treatment of human papilloma virus (HPV16+)-driven recurrent/metastatic head and neck cancer. The company is also developing CUE-102 targets Wilms' Tumor 1 protein in various cancers; CUE-103, a CUE-100 series drug product candidate; and Neo-STAT and RDI-STAT programs outside of oncology, including CUE-200, CUE-300, and CUE-400 series. It has collaboration agreements with LG Chem, Ltd. for the development of Immuno-STATs focused in the field of oncology; strategic collaboration and option agreement with Ono Pharmaceutical Co., Ltd. to advance CUE-401 for the treatment of autoimmune and inflammatory diseases; and license agreement with Albert Einstein College of Medicine. The company was formerly known as Imagen Biopharma, Inc. and changed its name to Cue Biopharma, Inc. in October 2016. Cue Biopharma, Inc. was incorporated in 2014 and is headquartered in Boston, Massachusetts.

Nuvectis Pharma NASDAQ:NVCT

$21.92 +1.20 (+5.79%)

Closing price 10/2/2026 04:00 PM Eastern

Extended Trading

$21.88 -0.04 (-0.16%)

As of 10/2/2026 07:30 PM Eastern

Nuvectis Pharma, Inc., a biopharmaceutical company, focuses on the development of precision medicines for the treatment of serious unmet medical needs in oncology. The company's lead product candidate is NXP800, a novel small molecule that is in Phase 1b clinical trials for the treatment of patients with platinum-resistant, ARID1a-mutated ovarian carcinoma. It is also developing NXP900, a small molecule drug candidate, which is in Phase 1a clinical trails that inhibits the Proto-oncogene c-Src and YES1 kinases. It has license agreement with the CRT Pioneer Fund for the NXP800 and any of related derivatives; and the University of Edinburgh for the NXP900 and any of associated derivatives. The company was formerly known as Centry Pharma, Inc. and changed its name to Nuvectis Pharma, Inc. in July 2021. Nuvectis Pharma, Inc. was incorporated in 2020 and is based in Fort Lee, New Jersey.

Olema Pharmaceuticals NASDAQ:OLMA

$8.23 -0.04 (-0.48%)

Closing price 10/2/2026 04:00 PM Eastern

Extended Trading

$8.23 0.00 (0.00%)

As of 10/2/2026 07:30 PM Eastern

Olema Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women's cancers. Its lead product candidate is OP-1250, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 3 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer; and OP-1250 combine with CDK4/6 inhibitors palbociclib, ribociclib, and alpelisib in Phase 1/2 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive human epidermal growth factor receptor 2-negative breast cancer, as well as develops OPERA-01 for the of ER+/HER2- advanced or metastatic breast cancer. The company was formerly known as CombiThera, Inc. and changed its name to Olema Pharmaceuticals, Inc. in March 2009. Olema Pharmaceuticals, Inc. was incorporated in 2006 and is headquartered in San Francisco, California.

Verastem NASDAQ:VSTM

$7.70 -0.20 (-2.53%)

Closing price 10/2/2026 04:00 PM Eastern

Extended Trading

$7.79 +0.09 (+1.17%)

As of 10/2/2026 07:30 PM Eastern

Verastem, Inc., a development-stage biopharmaceutical company, focuses on developing and commercializing drugs for the treatment of cancer in the United States. Its product candidates are Avutometinib, an orally available small molecule RAF/MEK clamp that inhibits the ras sarcoma RAF/MEK, ERK mitogen activated pathway kinase pathway which is involved in cell proliferation, migration, transformation, and survival of tumor cells; and Defactinib, an oral small molecule inhibitor of FAK and proline-rich tyrosine kinase for various solid tumors. The company is involved in clinical studies, including RAMP 301, a randomized global confirmatory trial to evaluate the combination of Avutometinib and Defactinib for the treatment of patients with recurrent low-grade serous ovarian cancer; RAMP 201, an adaptive two-part multicenter, parallel cohort, randomized open label trial to evaluate the efficacy and safety of Avutometinib and in combination with Defactinib; and FRAME, an investigation of Avutometinib and Defactinib in patients with KRAS mutant cancers and subsequent analyses; and RAMP 204 and 205. It has license agreements with Chugai Pharmaceutical Co., Ltd. for the development, commercialization, and manufacture of products containing Avutometinib; and Pfizer Inc. to research, develop, manufacture, and commercialize products containing Pfizer's inhibitors of FAK for therapeutic, diagnostic, and prophylactic uses in humans. In addition, it has a clinical collaboration agreement with Amgen, Inc. to evaluate the combination of Avutometinib with Amgen's KRAS-G12C inhibitor LUMAKRAS which in Phase 1/2 trial entitled RAMP 203; and a discovery and development collaboration with GenFleet Therapeutics to advance new programs targeting RAS pathway-driven cancers. Verastem, Inc. was incorporated in 2010 and is headquartered in Needham, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest CUE, OLMA, NVCT, and VSTM Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest CUE, OLMA, NVCT, and VSTM Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

CUE, OLMA, NVCT, and VSTM Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

CUE, OLMA, NVCT, and VSTM Company Descriptions

Cue Biopharma NASDAQ:CUE

Nuvectis Pharma NASDAQ:NVCT

Olema Pharmaceuticals NASDAQ:OLMA

Verastem NASDAQ:VSTM

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest CUE, OLMA, NVCT, and VSTM Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest CUE, OLMA, NVCT, and VSTM Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

CUE, OLMA, NVCT, and VSTM Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

CUE, OLMA, NVCT, and VSTM Company Descriptions

Cue Biopharma NASDAQ:CUE

Nuvectis Pharma NASDAQ:NVCT

Olema Pharmaceuticals NASDAQ:OLMA

Verastem NASDAQ:VSTM

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools